Bactiguard Holding AB (publ) (BACTI-B.ST)
SEK 37.2
(-2.11%)
SEK 37.2
(-2.11%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -89.98 Million SEK | -4563.32% |
| 2022 | -543 Thousand SEK | 74.79% |
| 2021 | -5.93 Million SEK | -133.64% |
| 2020 | 9.21 Million SEK | -63.21% |
| 2019 | 59.12 Million SEK | 213.96% |
| 2018 | 19.54 Million SEK | -41.42% |
| 2017 | 33.16 Million SEK | 91.96% |
| 2016 | 17.27 Million SEK | -17.84% |
| 2015 | 21.09 Million SEK | 163.14% |
| 2014 | -18.04 Million SEK | -145.44% |
| 2013 | 73.78 Million SEK | 173.16% |
| 2012 | 27.6 Million SEK | 590.53% |
| 2011 | -5.46 Million SEK | -109.23% |
| 2010 | 59.26 Million SEK | -38.58% |
| 2009 | 96.48 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 17.08 Million SEK | 1827.5% |
| 2024 Q1 | -5.64 Million SEK | 148.9% |
| 2024 Q2 | -989 Thousand SEK | -132.59% |
| 2023 Q4 | -6.2 Million SEK | 15.22% |
| 2023 FY | - SEK | -4563.32% |
| 2023 Q1 | -4.67 Million SEK | -979.85% |
| 2023 Q2 | -35.86 Million SEK | -667.62% |
| 2023 Q3 | -7.32 Million SEK | 79.59% |
| 2022 Q3 | 8.14 Million SEK | 704.05% |
| 2022 Q4 | 531 Thousand SEK | -93.48% |
| 2022 FY | - SEK | 74.79% |
| 2022 Q1 | -4 Million SEK | 74.27% |
| 2022 Q2 | 1.01 Million SEK | 125.31% |
| 2021 Q1 | 4.78 Million SEK | 1063.99% |
| 2021 Q3 | 3.19 Million SEK | -28.12% |
| 2021 Q4 | -15.55 Million SEK | -587.07% |
| 2021 FY | - SEK | -133.64% |
| 2021 Q2 | 4.44 Million SEK | -7.15% |
| 2020 Q2 | 15.14 Million SEK | 3.18% |
| 2020 Q1 | 14.67 Million SEK | 7.08% |
| 2020 FY | - SEK | -63.21% |
| 2020 Q3 | -2.22 Million SEK | -114.67% |
| 2020 Q4 | 411 Thousand SEK | 118.5% |
| 2019 FY | - SEK | 213.96% |
| 2019 Q4 | 13.7 Million SEK | -63.34% |
| 2019 Q3 | 37.38 Million SEK | 528.23% |
| 2019 Q2 | 5.95 Million SEK | -26.63% |
| 2019 Q1 | 8.11 Million SEK | 642.77% |
| 2018 Q3 | 8.33 Million SEK | -29.63% |
| 2018 Q4 | 1.09 Million SEK | -86.9% |
| 2018 FY | - SEK | -41.42% |
| 2018 Q1 | 3.08 Million SEK | -66.38% |
| 2018 Q2 | 11.84 Million SEK | 284.27% |
| 2017 Q4 | 9.16 Million SEK | -0.24% |
| 2017 Q3 | 9.19 Million SEK | 120.51% |
| 2017 FY | - SEK | 91.96% |
| 2017 Q2 | 4.16 Million SEK | -69.15% |
| 2017 Q1 | 13.51 Million SEK | 589.29% |
| 2016 Q3 | 11.72 Million SEK | 50.3% |
| 2016 Q4 | 1.96 Million SEK | -83.28% |
| 2016 Q1 | 426 Thousand SEK | -97.67% |
| 2016 FY | - SEK | -17.84% |
| 2016 Q2 | 7.79 Million SEK | 1730.75% |
| 2015 Q3 | 49.82 Million SEK | 4474.84% |
| 2015 Q1 | -4.25 Million SEK | 91.51% |
| 2015 FY | - SEK | 163.14% |
| 2015 Q2 | 1.08 Million SEK | 125.61% |
| 2015 Q4 | 18.24 Million SEK | -63.38% |
| 2014 Q2 | 23.35 Million SEK | 58.35% |
| 2014 Q4 | -50.09 Million SEK | -806.22% |
| 2014 FY | - SEK | -145.44% |
| 2014 Q3 | 7.09 Million SEK | -69.62% |
| 2014 Q1 | 14.74 Million SEK | -81.56% |
| 2013 Q3 | 4.73 Million SEK | -3.53% |
| 2013 Q4 | 79.98 Million SEK | 1590.24% |
| 2013 Q1 | 17.61 Million SEK | 1204.77% |
| 2013 Q2 | 4.9 Million SEK | -72.15% |
| 2013 FY | - SEK | 173.16% |
| 2012 Q2 | -1.01 Million SEK | 0.0% |
| 2012 FY | - SEK | 590.53% |
| 2012 Q4 | -1.59 Million SEK | -212.17% |
| 2012 Q3 | 1.42 Million SEK | 240.55% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | -109.23% |
| 2010 FY | - SEK | -38.58% |
| 2009 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | -16.675% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 121.846% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 121.846% |
| Arcoma AB | 6.24 Million SEK | 1540.173% |
| BICO Group AB (publ) | 322.3 Million SEK | 127.919% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 236.38% |
| CellaVision AB (publ) | 207.24 Million SEK | 143.418% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | -31.541% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | -222.02% |
| C-Rad AB (publ) | 48.9 Million SEK | 283.997% |
| Duearity AB (publ) | -24.77 Million SEK | -263.138% |
| Dignitana AB (publ) | -264 Thousand SEK | -33984.091% |
| Episurf Medical AB (publ) | -87.7 Million SEK | -2.602% |
| Getinge AB (publ) | 5.92 Billion SEK | 101.518% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | -33.802% |
| Iconovo AB (publ) | -35.33 Million SEK | -154.651% |
| Integrum AB (publ) | 8.76 Million SEK | 1127.013% |
| Luxbright AB (publ) | -23.86 Million SEK | -277.018% |
| Mentice AB (publ) | 28.87 Million SEK | 411.648% |
| OssDsign AB (publ) | -122.02 Million SEK | 26.257% |
| Paxman AB (publ) | 31.22 Million SEK | 388.136% |
| Promimic AB (publ) | -3.68 Million SEK | -2342.509% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 40.213% |
| SciBase Holding AB (publ) | -51.82 Million SEK | -73.613% |
| ScandiDos AB (publ) | -13.35 Million SEK | -573.72% |
| Sectra AB (publ) | 615.06 Million SEK | 114.63% |
| Sedana Medical AB (publ) | -51.67 Million SEK | -74.134% |
| Senzime AB (publ) | -118.82 Million SEK | 24.272% |
| SpectraCure AB (publ) | -20.96 Million SEK | -329.119% |
| Stille AB | 56.04 Million SEK | 260.565% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 97.175% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 171.09% |